Alumis Inc. $ALMS Stake Lifted by Trium Capital LLP

Trium Capital LLP grew its holdings in Alumis Inc. (NASDAQ:ALMS) by 17.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,122,111 shares of the company’s stock after buying an additional 474,072 shares during the period. Alumis accounts for approximately 4.9% of Trium Capital LLP’s portfolio, making the stock its 8th largest position. Trium Capital LLP’s holdings in Alumis were worth $12,457,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ALMS. CWM LLC grew its holdings in shares of Alumis by 1,028.7% during the third quarter. CWM LLC now owns 10,384 shares of the company’s stock worth $41,000 after buying an additional 9,464 shares during the last quarter. Kera Capital Partners Inc. acquired a new stake in Alumis during the 2nd quarter worth approximately $32,000. Corebridge Financial Inc. lifted its position in Alumis by 53.0% during the 1st quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock worth $65,000 after acquiring an additional 3,693 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Alumis by 199.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock valued at $32,000 after purchasing an additional 7,165 shares during the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after purchasing an additional 7,467 shares during the period.

Analyst Ratings Changes

ALMS has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research note on Monday. Wall Street Zen raised shares of Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, HC Wainwright upped their price objective on shares of Alumis from $14.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.40.

Alumis Price Performance

ALMS opened at $11.42 on Friday. Alumis Inc. has a 12 month low of $2.76 and a 12 month high of $12.44. The stock has a market capitalization of $1.19 billion, a P/E ratio of -2.82 and a beta of -1.87. The business has a 50 day simple moving average of $7.44 and a 200-day simple moving average of $5.18.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. Research analysts anticipate that Alumis Inc. will post -8.51 EPS for the current year.

Insider Activity at Alumis

In related news, major shareholder Foresite Labs, Llc acquired 200,000 shares of Alumis stock in a transaction that occurred on Monday, November 17th. The stock was purchased at an average price of $5.59 per share, for a total transaction of $1,118,000.00. Following the completion of the purchase, the insider directly owned 2,234,129 shares of the company’s stock, valued at approximately $12,488,781.11. This trade represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James B. Tananbaum acquired 200,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were bought at an average cost of $5.59 per share, for a total transaction of $1,118,000.00. Following the acquisition, the director owned 2,234,129 shares of the company’s stock, valued at $12,488,781.11. This represents a 9.83% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 2,788,875 shares of company stock worth $18,352,357. 40.70% of the stock is owned by company insiders.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.